Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Pliant Therapeutics Inc shares valued at $30,723 were sold by Cummings Keith Lamont on Jan 20 ’26. At $1.28 per share, Cummings Keith Lamont sold 24,002 shares. The insider’s holdings dropped to 297,214 shares worth approximately $0.39 million following the completion of this transaction.
Also, Cheung Lily sold 7,534 shares, netting a total of over 9,644 in proceeds. Following the sale of shares at $1.28 each, the insider now holds 44,847 shares.
Before that, Coulie Bernard had sold 89,375 shares from its account. In a trade valued at $114,400, the President and CEO traded Pliant Therapeutics Inc shares for $1.28 each. Upon closing the transaction, the insider’s holdings decreased to 89,375 shares, worth approximately $0.66 million.
As published in a research note from JP Morgan on October 10, 2025, Pliant Therapeutics Inc [PLRX] has been rated down from a Neutral to an Underweight. As of March 04, 2025, Needham has decreased its “Buy” rating to a “Hold” for PLRX. Earlier on March 03, 2025, Stifel downgraded its rating. Their new recommendation was “a Hold” for PLRX stock which previously was a “a Buy”.
Analyzing PLRX Stock Performance
On last trading session, Pliant Therapeutics Inc [NASDAQ: PLRX] rose 3.17% to $1.3. The stock’s lowest price that day was $1.27, but it reached a high of $1.34 in the same session. During the last five days, there has been a drop of approximately -0.76%. Over the course of the year, Pliant Therapeutics Inc shares have dropped approximately -88.26%.
Is Pliant Therapeutics Inc subject to short interest?
Stocks of Pliant Therapeutics Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.89 million shares to 3.1 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 3.99 million shares. A decline of -28.82% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.74 of the overall float, the days-to-cover ratio (short ratio) decline to 1.74.
Which companies own the most shares of Pliant Therapeutics Inc (PLRX)?
In terms of Pliant Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 40 in the next 12 months, up nearly 3074.6% from the previous closing price of $1.26. Analysts anticipate Pliant Therapeutics Inc stock to reach 48 by 2026, with the lowest price target being 2. In spite of this, 5 analysts ranked Pliant Therapeutics Inc stock as Buy at the end of 2026.
